- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Submits Application to U.S. FDA Seeking Approval of a Mebendazole Chewable Tablet for the Treatment of Soil-Transmitted Helminthiasis
Chewable formulation of mebendazole will address an unmet need in treating intestinal worms in young children
Janssen’s IMBRUVICA® (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients
Recommendation based on RESONATE™-2 trial which showed IMBRUVICA significantly improved progression-free survival and prolonged overall survival versus chlorambucil
Global Public-Private Partnership Announces Publication of Positive Phase 1 Data for Ebola Vaccine Regimen in JAMA
First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization. An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected countries and to prevent future outbreaks. Partners involved in the clinical program for the Ebola vaccine regimen include the Janssen Pharmaceutical Companies of Johnson & Johnson, the London School of Hygiene & Tropical Medicine, the University of Oxford, Inserm, Bavarian Nordic and Europe’s Innovative Medicines Initiative.
New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban with Warfarin
Real-world findings show balance of benefit and risk of XARELTO® (rivaroxaban) with respect to ischemic stroke and a reduction in intracranial hemorrhage in routine clinical practice, further confirming the efficacy and safety profile observed in ROCKET AF
Real-World Study Further Confirms Safety Profile of XARELTO® in Nearly 45,000 People with Non-Valvular Atrial Fibrillation (NVAF), Including Those with Concomitant Diabetes
Study definitively confirms original results of ROCKET AF and adds to growing body of real-world evidence, informing the safety of XARELTO® in high-risk patients with NVAF
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)
Includes several late breaking and oral presentations from across R&D pipeline Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens
Real-World Data on XARELTO® in Patients with Non-Valvular Atrial Fibrillation and Diabetes Among 14 Presentations at American College of Cardiology’s 65th Annual Scientific Session
New data add to growing body of real-world evidence supporting physicians and hospitals in optimizing patient care for those at risk of stroke or blood clots